Regarding hematological toxicity, the incidence of grade 3 or more anemia (23%) was higher than expected with R-CHOP alone (7–8% in POLARIX or GOYA trials), although it was still in the range of other R-CHOP-X studies, showing an incidence between 10 and 35%.9 This evidence concerns the gene DDIT3 and anemia (phenotype).